Profile data is unavailable for this security.
About the company
Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
- Revenue in AUD (TTM)95.50m
- Net income in AUD35.64m
- Incorporated1999
- Employees16.00
- LocationClinuvel Pharmaceuticals LtdLevel 22, 535 Bourke StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39660-4900
- Fax+61 39660-4909
- Websitehttps://www.clinuvel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Henan Taloph Pharmaceutical Stock Co Ltd | 419.90m | 19.07m | 669.88m | 2.35k | 36.11 | 2.00 | -- | 1.60 | 0.1515 | 0.1515 | 3.39 | 2.74 | 0.5571 | 2.93 | 2.06 | 836,256.80 | 2.67 | 0.272 | 5.80 | 0.4981 | 27.64 | 27.97 | 4.79 | 0.5501 | 0.8146 | 2.65 | 0.3911 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
| Esperion Therapeutics Inc | 455.56m | -133.79m | 674.71m | 240.00 | -- | -- | -- | 1.48 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Aquestive Therapeutics Inc | 90.82m | -54.26m | 679.04m | 135.00 | -- | -- | -- | 7.48 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Katakura Industries Co., Ltd. | 378.06m | 28.69m | 679.69m | 1.04k | 22.13 | 0.8256 | 15.79 | 1.80 | 87.92 | 87.92 | 1,158.05 | 2,357.16 | 0.2725 | 1.99 | 5.37 | 36,650,960.00 | 2.17 | 2.35 | 2.79 | 3.34 | 38.62 | 37.75 | 7.97 | 8.32 | 2.56 | -- | 0.1026 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| Revance Therapeutics Inc | 380.85m | -278.79m | 681.10m | 597.00 | -- | -- | -- | 1.79 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Zhejiang Shapuaisi Pharmaceutical Co Ltd | 107.89m | -18.09m | 682.08m | 1.39k | -- | 1.90 | -- | 6.32 | -0.2245 | -0.2245 | 1.34 | 4.44 | 0.2408 | 2.86 | 13.81 | 365,039.00 | -3.93 | -0.7573 | -4.52 | -0.8713 | 50.29 | 58.02 | -16.32 | -2.45 | 1.04 | -- | 0.1236 | -- | 17.37 | 1.21 | -43.23 | -- | 30.36 | -- |
| Clinuvel Pharmaceuticals Limited | 95.50m | 35.64m | 685.33m | 16.00 | 19.52 | 3.38 | 18.63 | 7.18 | 0.7014 | 0.7014 | 1.87 | 4.05 | 0.4496 | -0.1099 | 3.94 | -- | 16.78 | 18.81 | 19.05 | 21.04 | 101.16 | 102.61 | 37.31 | 39.00 | 8.39 | 10.94 | 0.0043 | 7.42 | 16.15 | 24.75 | 16.44 | 14.47 | 84.96 | 14.87 |
| YungShin Global Holding Corp | 353.16m | 49.99m | 686.96m | 1.57k | 13.74 | 1.96 | 10.18 | 1.95 | 3.95 | 3.95 | 27.91 | 27.66 | 0.5953 | 1.47 | 5.51 | -- | 9.10 | 6.64 | 13.58 | 10.20 | 43.28 | 45.11 | 15.29 | 10.45 | 1.35 | -- | 0.1034 | 70.94 | -3.88 | -1.33 | -1.40 | 3.34 | -29.00 | 0.893 |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 511.63m | -50.28m | 689.49m | 5.51k | -- | 1.22 | -- | 1.35 | -0.2975 | -0.2975 | 3.03 | 3.34 | 0.5288 | 1.52 | 13.04 | 435,209.10 | -5.39 | 0.8648 | -6.97 | 1.18 | 61.81 | 74.87 | -10.19 | 1.45 | 1.36 | -9.98 | 0.2375 | 216.36 | 3.12 | -6.19 | 124.25 | -- | -16.51 | -- |
| Zevra Therapeutics Inc | 36.98m | -101.37m | 702.60m | 65.00 | -- | 11.20 | -- | 19.00 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.52m | 3.03% |
| Vanguard Investments Australia Ltd.as of 30 Sep 2024 | 777.03k | 1.55% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 751.50k | 1.50% |
| BlackRock Fund Advisorsas of 02 Oct 2024 | 472.41k | 0.94% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 436.96k | 0.87% |
| DFA Australia Ltd.as of 30 Sep 2024 | 250.99k | 0.50% |
| AllianceBernstein Ltd.as of 30 Jun 2024 | 199.35k | 0.40% |
| BlackRock Asset Management North Asia Ltd.as of 31 Jul 2024 | 130.16k | 0.26% |
| Charles Schwab Investment Management, Inc.as of 03 Oct 2024 | 82.78k | 0.17% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 41.25k | 0.08% |
